{"product_id":"cancer-as-a-metabolic-disease-9780470584927","title":"Cancer as a Metabolic Disease","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention.  It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.   However, Warburg did not link his theory to the \"hallmarks of cancer\" and thus his theory was discredited.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“This book offers a refreshing perspective for anyone wanting to get a comprehensive background on the newer emerging interest in targeting cancer metabolism for therapy.”  (\u003ci\u003eDoody’s\u003c\/i\u003e, 11 January 2013)\u003c\/p\u003e \u003cp\u003e“For the first time, an entire issue is being devoted to a review article based on a recent medical book. This is a departure from our usual format, but I think you will agree that this topic warrants the detailed treatment we have given it . . .This book should be required reading for all scientifically literate people who are involved in the cancer problem.”  (\u003ci\u003eAdvances in Cancer Treatment\u003c\/i\u003e, 1 October 2012)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eForword xiii\u003c\/p\u003e \u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1. Images of Cancer 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHow Cancer is Viewed 2\u003c\/p\u003e \u003cp\u003eReferences 13\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2. Confusion Surrounds the Origin of Cancer 15\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe Oncogenic Paradox 18\u003c\/p\u003e \u003cp\u003eHallmarks of Cancer 18\u003c\/p\u003e \u003cp\u003eReassessment 26\u003c\/p\u003e \u003cp\u003eReferences 27\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Cancer Models 31\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eProblems with Some Cancer Models 31\u003c\/p\u003e \u003cp\u003eAnimal Charges as a Major Impediment to Cancer Research 38\u003c\/p\u003e \u003cp\u003eProblems with Tumor Histological Classification 39\u003c\/p\u003e \u003cp\u003ePersonal Perspective on Cancer 44\u003c\/p\u003e \u003cp\u003eReferences 45\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4. Energetics of Normal Cells and Cancer Cells 47\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMetabolic Homeostasis 47\u003c\/p\u003e \u003cp\u003eThe Constancy of the ∆\u003ci\u003eG\u003c\/i\u003e’\u003csub\u003eATP\u003c\/sub\u003e 54\u003c\/p\u003e \u003cp\u003eATP Production in Normal Cells and Tumor Cells 55\u003c\/p\u003e \u003cp\u003eEnergy Production Through Glucose Fermentation 57\u003c\/p\u003e \u003cp\u003eGlutaminolysis with or without Lactate Production 61\u003c\/p\u003e \u003cp\u003eTransamination Reactions 64\u003c\/p\u003e \u003cp\u003eTCA Cycle, Substrate-Level Phosphorylation 66\u003c\/p\u003e \u003cp\u003eCholesterol Synthesis and Hypoxia 67\u003c\/p\u003e \u003cp\u003eSummary 67\u003c\/p\u003e \u003cp\u003eReferences 68\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5. Respiratory Dysfunction in Cancer Cells 73\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eNormal Mitochondria 74\u003c\/p\u003e \u003cp\u003eMorphological Defects in Tumor Cell Mitochondria 77\u003c\/p\u003e \u003cp\u003eProteomic Abnormalities in Tumor Cell Mitochondria 79\u003c\/p\u003e \u003cp\u003eLipidomic Abnormalities in Tumor Cell Mitochondria 81\u003c\/p\u003e \u003cp\u003eCardiolipin: A Mitochondrial-Specific Lipid 83\u003c\/p\u003e \u003cp\u003eCardiolipin and Abnormal Energy Metabolism in Tumor Cells 85\u003c\/p\u003e \u003cp\u003eComplicating Influence of the In Vitro Growth Environment on Cardiolipin Composition and Energy Metabolism 92\u003c\/p\u003e \u003cp\u003eMitochondrial Uncoupling and Cancer 97\u003c\/p\u003e \u003cp\u003eCancer Cell Heat Production and Uncoupled Mitochondria 98\u003c\/p\u003e \u003cp\u003ePersonal Perspective 99\u003c\/p\u003e \u003cp\u003eSummary 100\u003c\/p\u003e \u003cp\u003eReferences 101\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6. The Warburg Dispute 107\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSidney Weinhouse’s Criticisms of the Warburg Theory 108\u003c\/p\u003e \u003cp\u003eAlan Aisenberg’s Criticisms of the Warburg Theory 110\u003c\/p\u003e \u003cp\u003eSidney Colowick’s Assessment of the Aisenberg Monograph 113\u003c\/p\u003e \u003cp\u003eApples and Oranges 114\u003c\/p\u003e \u003cp\u003eReferences 116\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Is Respiration Normal in Cancer Cells? 119\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePseudo-Respiration 119\u003c\/p\u003e \u003cp\u003eHow Strong is the Scientific Evidence Showing that Tumor Cells can Produce Energy Through OxPhos? 124\u003c\/p\u003e \u003cp\u003eOxPhos Origin of ATP in Cancer Cells Reevaluated 124\u003c\/p\u003e \u003cp\u003eWhat About OxPhos Expression in Other Tumors? 127\u003c\/p\u003e \u003cp\u003eThe Pedersen Review on Tumor Mitochondria and the Bioenergetics of Cancer Cells 128\u003c\/p\u003e \u003cp\u003eReferences 129\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8. Is Mitochondrial Glutamine Fermentation a Missing Link in the Metabolic Theory of Cancer? 133\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAmino Acid Fermentation can Maintain Cellular Energy Homeostasis During Anoxia 133\u003c\/p\u003e \u003cp\u003eEvidence Suggesting that Metastatic Mouse Cells Derive Energy from Glutamine Fermentation 134\u003c\/p\u003e \u003cp\u003eFermentation Energy Pathways can Drive Cancer Cell Viability Under Hypoxia 138\u003c\/p\u003e \u003cp\u003eCompeting Explanations for the Metabolic Origin of Cancer 141\u003c\/p\u003e \u003cp\u003eChapter Summary 143\u003c\/p\u003e \u003cp\u003eReferences 143\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9. Genes, Respiration, Viruses, and Cancer 145\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDoes Cancer have a Genetic Origin? 145\u003c\/p\u003e \u003cp\u003eRespiratory Insufficiency as the Origin of Cancer 150\u003c\/p\u003e \u003cp\u003eGermline Mutations, Damaged Respiration, and Cancer 154\u003c\/p\u003e \u003cp\u003eSomatic Mutations and Cancer 158\u003c\/p\u003e \u003cp\u003eRevisiting the Oncogene Theory 160\u003c\/p\u003e \u003cp\u003eMitochondrial Mutations and the Absence or Presence of Cancer 163\u003c\/p\u003e \u003cp\u003eViral Infection, Damaged Respiration, and the Origin of Cancer 165\u003c\/p\u003e \u003cp\u003eSummary 168\u003c\/p\u003e \u003cp\u003eReferences 168\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10. Respiratory Insufficiency, the Retrograde Response, and the Origin of Cancer 177\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe Retrograde (RTG) Response: An Epigenetic System Responsible for Nuclear Genomic Stability 177\u003c\/p\u003e \u003cp\u003eInflammation Injures Cellular Respiration 181\u003c\/p\u003e \u003cp\u003eHypoxia-Inducible Factor (HIF) Stability is Required for the Origin of Cancer 182\u003c\/p\u003e \u003cp\u003eMitochondria and the Mutator Phenotype 183\u003c\/p\u003e \u003cp\u003eCalcium Homeostasis, Aneuploidy, and Mitochondrial Dysfunction 186\u003c\/p\u003e \u003cp\u003eMitochondrial Dysfunction and Loss of Heterozygosity (LOH) 187\u003c\/p\u003e \u003cp\u003eTissue Inflammation, Damaged Respiration, and Cancer 188\u003c\/p\u003e \u003cp\u003eReferences 189\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11. Mitochondria: The Ultimate Tumor Suppressor 195\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMitochondrial Suppression of Tumorigenicity 195\u003c\/p\u003e \u003cp\u003eNormal Mitochondria Suppress Tumorigenesis in Cybrids 196\u003c\/p\u003e \u003cp\u003eEvidence from rho\u003csup\u003e0\u003c\/sup\u003e Cells 198\u003c\/p\u003e \u003cp\u003eNormal Mitochondria Suppress Tumorigenesis In Vivo 199\u003c\/p\u003e \u003cp\u003eNormal Mouse Cytoplasm Suppresses Tumorigenic Phenotypes 200\u003c\/p\u003e \u003cp\u003eEnhanced Differentiation and Suppressed Tumorigenicity in the Liver Microenvironment 202\u003c\/p\u003e \u003cp\u003eSummary of Nuclear-Cytoplasmic Transfer Experiments 203\u003c\/p\u003e \u003cp\u003eReferences 204\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12. Abnormalities in Growth Control, Telomerase Activity, Apoptosis, and Angiogenesis Linked to Mitochondrial Dysfunction 207\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGrowth Signaling Abnormalities and Limitless Replicative Potential 208\u003c\/p\u003e \u003cp\u003eLinking Telomerase Activity to Cellular Energy and Cancer 209\u003c\/p\u003e \u003cp\u003eEvasion of Programmed Cell Death (Apoptosis) 209\u003c\/p\u003e \u003cp\u003eSustained Vascularity (Angiogenesis) 210\u003c\/p\u003e \u003cp\u003eReferences 211\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13. Metastasis 215\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMetastasis Overview 215\u003c\/p\u003e \u003cp\u003eCellular Origin of Metastasis 217\u003c\/p\u003e \u003cp\u003eMacrophages and Metastasis 221\u003c\/p\u003e \u003cp\u003eCarcinoma of Unknown Primary Origin 232\u003c\/p\u003e \u003cp\u003eMany Metastatic Cancers Express Multiple Macrophage Properties 233\u003c\/p\u003e \u003cp\u003eLinking Metastasis to Mitochondrial Dysfunction 233\u003c\/p\u003e \u003cp\u003eRevisiting the “Seed and Soil” Hypothesis of Metastasis 235\u003c\/p\u003e \u003cp\u003eRevisiting the Mesenchymal Epithelial Transition (MET) 236\u003c\/p\u003e \u003cp\u003eGenetic Heterogeneity in Cancer Metastases 237\u003c\/p\u003e \u003cp\u003eTransmissible Metastatic Cancers 240\u003c\/p\u003e \u003cp\u003eThe Absence of Metastases in Crown-Gall Plant Tumors 240\u003c\/p\u003e \u003cp\u003eChapter Summary 241\u003c\/p\u003e \u003cp\u003eReferences 241\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14. Mitochondrial Respiratory Dysfunction and the Extrachromosomal Origin of Cancer 253\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eConnecting the Links 254\u003c\/p\u003e \u003cp\u003eAddressing the Oncogenic Paradox 255\u003c\/p\u003e \u003cp\u003eIs Cancer Many Diseases or a Singular Disease of Energy Metabolism? 258\u003c\/p\u003e \u003cp\u003eReferences 258\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15. Nothing in Cancer Biology Makes Sense Except in the Light of Evolution 261\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eRevisiting Growth Advantage of Tumor Cells, Mutations, and Evolution 262\u003c\/p\u003e \u003cp\u003eTumor Cell Fitness in Light of the Evolutionary Theory of Rick Potts 269\u003c\/p\u003e \u003cp\u003eCancer Development and Lamarckian Inheritance 271\u003c\/p\u003e \u003cp\u003eCan Teleology Explain Cancer? 272\u003c\/p\u003e \u003cp\u003eReferences 272\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16. Cancer Treatment Strategies 277\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCurrent Status of Cancer Treatment 277\u003c\/p\u003e \u003cp\u003eThe “Standard of Care” for Glioblastoma Management 280\u003c\/p\u003e \u003cp\u003eReferences 285\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17. Metabolic Management of Cancer 291\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIs it Dietary Content or Dietary Composition that Primarily Reduces Tumor Growth? 292\u003c\/p\u003e \u003cp\u003eDietary Energy Reduction and Therapeutic Fasting in Rodents and Humans 294\u003c\/p\u003e \u003cp\u003eKetogenic Diets 295\u003c\/p\u003e \u003cp\u003eGlucagon and Insulin 297\u003c\/p\u003e \u003cp\u003eBasal Metabolic Rate 298\u003c\/p\u003e \u003cp\u003eKetones and Glucose 298\u003c\/p\u003e \u003cp\u003eMetabolic Management of Brain Cancer Using the KD 299\u003c\/p\u003e \u003cp\u003eGlucose Accelerates Tumor Growth! 301\u003c\/p\u003e \u003cp\u003eGlucose Regulates Blood Levels of Insulin and Insulin-Like Growth Factor 1 302\u003c\/p\u003e \u003cp\u003eDietary Energy Reduction is Antiangiogenic 302\u003c\/p\u003e \u003cp\u003eDietary Energy Reduction Targets Abnormal Tumor Vessels 307\u003c\/p\u003e \u003cp\u003eDietary Energy Reduction is Proapoptotic 309\u003c\/p\u003e \u003cp\u003eDietary Energy Reduction is Anti-Inflammatory 310\u003c\/p\u003e \u003cp\u003eTargeting Energy Metabolism in Advanced Cancer 314\u003c\/p\u003e \u003cp\u003eDifferential Response of Normal Cells and Tumor Cells to Energy Stress 316\u003c\/p\u003e \u003cp\u003eDietary Energy Reduction is Anti-Invasive in Experimental Glioblastoma 318\u003c\/p\u003e \u003cp\u003eInfluence of Growth Site and Host on Tumor Progression 322\u003c\/p\u003e \u003cp\u003eImplications of Dietary Energy Reduction for Anticancer Therapeutics 324\u003c\/p\u003e \u003cp\u003eTargeting Glucose 325\u003c\/p\u003e \u003cp\u003eMetformin 326\u003c\/p\u003e \u003cp\u003eSynergistic Interaction of the Restricted Ketogenic Diet (KD-R) and 2-Deoxyglucose (2-DG) 327\u003c\/p\u003e \u003cp\u003eCan Synergy Occur with the KD-R and Hyperbaric Oxygen Therapy? 331\u003c\/p\u003e \u003cp\u003eTargeting Glutamine 333\u003c\/p\u003e \u003cp\u003eGlutamine Targeting Inhibits Systemic Metastasis 334\u003c\/p\u003e \u003cp\u003eTargeting Phagocytosis 339\u003c\/p\u003e \u003cp\u003eTargeting the Microenvironment 340\u003c\/p\u003e \u003cp\u003eDietary Energy Reduction as a Mitochondrial Enhancement Therapy (MET) 341\u003c\/p\u003e \u003cp\u003eSummary 341\u003c\/p\u003e \u003cp\u003eReferences 341\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18. Patient Implementation of Metabolic Therapies for Cancer Management 355\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 355\u003c\/p\u003e \u003cp\u003eGuidelines for Implementing the Restricted Ketogenic Diet as a Treatment Strategy for Cancer 356\u003c\/p\u003e \u003cp\u003eComplicating Issues for Implementing the KD-R as a Treatment Strategy for Cancer 366\u003c\/p\u003e \u003cp\u003eRadiation and Chemotherapy is a Standard Treatment for Many Malignant Cancers 366\u003c\/p\u003e \u003cp\u003eCompliance 367\u003c\/p\u003e \u003cp\u003eCancer as a Genetic Disease 367\u003c\/p\u003e \u003cp\u003eMechanism of Action? 368\u003c\/p\u003e \u003cp\u003eCachexia 368\u003c\/p\u003e \u003cp\u003eSummary 369\u003c\/p\u003e \u003cp\u003eReferences 370\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19. Cancer Prevention 375\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCell Phones and Cancer 376\u003c\/p\u003e \u003cp\u003eAlzheimer’s Disease and Cancer Risk 377\u003c\/p\u003e \u003cp\u003eKetone Metabolism Reduces Cancer Risk 378\u003c\/p\u003e \u003cp\u003eMitochondrial Enhancement Therapy 379\u003c\/p\u003e \u003cp\u003eTherapeutic Fasting and Cancer Prevention 379\u003c\/p\u003e \u003cp\u003eAutophagy and Autolytic Cannibalism: A Thermodynamic Approach to Cancer Prevention 381\u003c\/p\u003e \u003cp\u003eCancer Prevention by Following Restricted Ketogenic Diet 382\u003c\/p\u003e \u003cp\u003eReferences 384\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20. Case Studies and Personal Experiences in Using the Ketogenic Diet for Cancer Management 387\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEffects of a Ketogenic Diet on Tumor Metabolism and Nutritional Status in Pediatric Oncology Patients: Comments from Dr. Linda Nebeling 387\u003c\/p\u003e \u003cp\u003eRaffi’s Story: Comments from Miriam Kalamian 389\u003c\/p\u003e \u003cp\u003eBiological Plausibility that Cancer is a Metabolic Disease Dependent for Growth on Glucose and Glutamine: Comments from Dr. Bomar Herrin 395\u003c\/p\u003e \u003cp\u003eUsing the Restricted Ketogenic Diet for Brain Cancer Management: Comments from Neuro-Oncologist, Dr. Kraig Moore 397\u003c\/p\u003e \u003cp\u003eThe Ketogenic Diet for Brain Cancer Management: Comments from Beth Zupec-Kania 400\u003c\/p\u003e \u003cp\u003eSummary 402\u003c\/p\u003e \u003cp\u003eReferences 403\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21. Conclusions 405\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMajor Conclusions 407\u003c\/p\u003e \u003cp\u003eReferences 408\u003c\/p\u003e \u003cp\u003eIndex 409\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402371309911,"sku":"9780470584927","price":112.46,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470584927.jpg?v=1730480193","url":"https:\/\/bookcurl.com\/products\/cancer-as-a-metabolic-disease-9780470584927","provider":"Book Curl","version":"1.0","type":"link"}